Metropolis Healthcare reported a 15.4% YoY rise in net profit at ₹31.4 crore for Q3 FY25, up against ₹27.2 crore from the corresponding quarter a year ago.
Revenue from operations rose by 11% at ₹322.8 crore against ₹291 crore in Q3 FY24. The company’s EBITDA jumped 11.2% in the December quarter to ₹72 crore from ₹64.8 crore in the previous fiscal. The EBITDA margin was stable at 22.3% and did not change much from the year-ago period. The company over time continued extending into diagnostics, though more on its efficiency in running the business to become stronger.
In the National Stock Exchange, shares of Metropolis Healthcare is trading at ₹1869 which is a 3.49% gain than the previous close. The stock has witnessed a total of 7.17% gain in the last one year.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
